62474 Federal Register / Vol. 71, No. 206 / Wednesday, October 25, 2006 / Notices 

burden of the collection of information 

on respondents, including through the 

use of automated collection techniques 

or other forms of information 

technology. Written comments should 

be received within 60 days of this 

notice. 

Proposed Project 

Follow-up Study of Chronic Fatigue 

Syndrome in Georgia—Reinstatement–

0920–0638—Coordinating Center for 

Infectious Diseases (CCID), Centers for 

Disease Control and Prevention (CDC). 

Background and Brief Description 

CDC is planning a follow-up study of 

Chronic Fatigue Syndrome (CFS) in 

metropolitan, urban and rural 

communities in Georgia. This is in 

response to Congressional 

recommendations that the Centers for 

Disease Control and Prevention (CDC) 

sustain efforts to identify biomarkers for 

CFS, educate health care providers 

about the diagnosis and treatment of 

CFS, and better inform the public about 

it to aid early detection and improve 

patient care. 

In 2004, OMB approved the 

information collection, Survey of 

Chronic Fatigue Syndrome and Chronic 

Unwellness in Georgia, under OMB 

Number 0920–0638. This study 

provided baseline information on CFS 

and other unexplained fatiguing illness 

in metropolitan, urban, and rural 

regions in Georgia. Data from the 

proposed Follow-up Study of Chronic 

Fatigue Syndrome in Georgia will be 

used to describe the clinical course of 

CFS and evaluate behavioral and 

biochemical factors associated with 

outcome. This follow-up study will also 

determine access to and utilization of 

health care by persons with CFS and 

measure direct and indirect economic 

burden due to the illness. As part of a 

control strategy, the information from 

this follow-up study will be used in 

national and pilot regional provider 

education programs designed to teach 

health care providers how to evaluate, 

diagnose and manage patients with CFS. 

The proposed study builds on 

information from the Georgia survey 

with the objective of collecting clinical 

information that will help in the 

treatment of CFS and will help to 

interpret results obtained from testing 

biologic specimens (i.e., identify 

biomarkers of CFS). This follow-up 

study begins with a detailed telephone 

interview of persons who participated 

in the earlier survey and volunteered to 

be contacted again. The interview is 

similar (with minor modifications) to 

the original interview and is intended to 

obtain additional data on participant 

health status during the last twelvemonth period. Eligible subjects with 

CFS, other fatiguing illnesses, and well 

controls will be asked to participate in 

clinical evaluations. 

ESTIMATED ANNUALIZED BURDEN HOURS

Respondents Number of 

respondents 

Number 

responses 

per 

respondent 

Average 

burden per 

response 

(in hours) 

Total 

burden 

hours 

Telephone interview ......................................................................................... 2,870 1 30/60 1,435

Clinical Evaluation ........................................................................................... 338 1 450/60 2,535 

Total .......................................................................................................... ........................ ........................ ........................ 3,970 

Dated: October 19, 2006. 

Joan F. Karr, 

Acting Reports Clearance Officer, Centers for 

Disease Control and Prevention. 

[FR Doc. E6–17853 Filed 10–24–06; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Statement of Organization, Functions, 

and Delegations of Authority 

Part C (Centers for Disease Control 

and Prevention) of the Statement of 

Organization, Functions, and 

Delegations of Authority of the 

Department of Health and Human 

Services (45 FR 67772–76, dated 

October 14, 1980, and corrected at 45 FR 

69296, October 20, 1980, as amended 

most recently at 71 FR 50065, dated 

August 14, 2006), is amended to reflect 

the establishment of the Healthy Aging 

Program within the Division of Adult 

and Community Health, National Center 

for Chronic Disease Prevention and 

Health Promotion, Coordinating Center 

for Health Promotion, Centers for 

Disease Control and Prevention. 

Section C–B, Organization and 

Functions, is hereby amended as follow: 

After the Office of the Director 

(CUCE1), Division of Adult and 

Community Health (CUCE) National 

Center for Chronic Disease Prevention 

and Health Promotion (CUC), insert the 

following: 

Healthy Aging Program (CUCE2). (1) 

Serves as an active link between public 

health and aging services networks to 

provide leadership in health promotion 

and disease prevention for older adults; 

(2) provides scientific expertise and 

rigor to health promoting strategies and 

interventions through the use of data 

and research; (3) disseminates 

prevention messages, programs, and 

policies; (4) contributes to the capacity 

of systems and organizations to improve 

the health of older adults; (5) 

administers grants, cooperative 

agreements, contracts, and other 

procurement requests to implement 

evidence-based health promotion 

interventions and disseminates health 

aging messages; (6) promotes expanding 

prevention research for older adults by 

supporting the Prevention Research 

Centers Healthy Aging Research 

Network (PRC–HAN); (7) administers 

data into action through the 

development of The State of Aging and 

Health in America report series; (8) 

collaborates with aging organizations to 

expand the reach to professionals, the 

public, and the media through the 

development and evaluation of webbased health promotion modules and 

media backgrounders on various older 

adult health topics; and (9) directs and 

disseminates the national public health 

and action plan for brain health as part 

of the Alzheimer’s disease segment of 

the Healthy Aging Program. 

Delete in its entirety the title and 

functional statement for the Healthcare 

and Aging Studies Branch (CUCEC), and 

insert the following: Arthritis, Epilepsy 

and Quality of Life Branch (CUCEC). (1) 

Directs and supports activities that 

increase the overall quality of life for 

people affected by arthritis; (2) directs 

and supports activities that improve 

medical care, improve communication 

and combat stigma, enhance selfmanagement, support surveillance and 

prevention research, and increase public 

awareness and knowledge about 

mstockstill on PROD1PC61 with NOTICES

Federal Register / Vol. 71, No. 206 / Wednesday, October 25, 2006 / Notices 62475 

epilepsy; (3) directs and administers the 

development of a national, state, and 

local surveillance system of tracking 

health-related quality of life (HRQOL) 

among U.S. residents; (4) administers 

grants, cooperative agreements, 

contracts, and other procurement 

requests to implement evidence-based 

health promotion interventions and 

disseminate arthritis prevention and 

epilepsy education messages; (5) 

develops, validates, and refines HRQOL 

measure for use in tracking and 

prevention research at each life stage; 

(6) directs and coordinates the 

evaluation of community and statebased intervention programs for arthritis 

and epilepsy; (7) developes arthritis 

epidemiology capacity and other 

arthritis programmatic capabilities in 

state health department settings; and (8) 

disseminates health promotion and 

disease prevention information through 

national advocacy partners for arthritis 

and epilepsy. 

Dated: October 12, 2006. 

William H. Gimson, 

Chief Operating Officer, Centers for Disease 

Control and Prevention (CDC). 

[FR Doc. 06–8869 Filed 10–24–06; 8:45 am] 

BILLING CODE 4160–18–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. 2006F–0409] 

Safe Foods Corporation; Filing of Food 

Additive Petition 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing 

that Safe Foods Corporation has filed a 

petition proposing that the food additive 

regulations be amended to expand the 

conditions for the safe use of 

cetylpyridinium chloride as an 

antimicrobial agent in a pre-chiller or 

post-chiller solution for application to 

raw poultry carcasses. 

DATES: Submit written or electronic 

comments on the petitioner’s 

environmental assessment by November 

24, 2006. 

ADDRESSES: Submit written comments 

to the Division of Dockets Management 

(HFA–305), Food and Drug 

Administration, 5630 Fishers Lane, rm. 

1061, Rockville, MD 20852. Submit 

electronic comments to http:// 

www.fda.gov/dockets/ecomments. 

FOR FURTHER INFORMATION CONTACT: 

Raphael Davy, Center for Food Safety 

and Applied Nutrition (HFS–265), Food 

and Drug Administration, 5100 Paint 

Branch Pkwy., College Park, MD 20740, 

301–436–1272. 

SUPPLEMENTARY INFORMATION: Under the 

Federal Food, Drug, and Cosmetic Act 

(section 409(b)(5) (21 U.S.C. 348(b)(5))), 

notice is given that a food additive 

petition (FAP 6A4767) has been filed by 

Safe Foods Corporation, c/o Keller and 

Heckman LLP, 1001 G St. NW., suite 

500 West, Washington, D.C. 20001. The 

petition proposes to amend the food 

additive regulations in § 173.375 

Cetylpyridinium chloride (21 CFR 

173.375) to expand the conditions for 

the safe use of cetylpyridinium chloride 

as an antimicrobial agent in a pre-chiller 

or post-chiller solution for application 

to raw poultry carcasses. 

The potential environmental impact 

of this action is being reviewed. To 

encourage public participation 

consistent with regulations issued under 

the National Environmental Policy Act 

(40 CFR 1501.4(b)), the agency is 

placing the environmental assessment 

submitted with the petition that is the 

subject of this notice on public display 

at the Division of Dockets Management 

(see ADDRESSES) for public review and 

comment. Interested persons may 

submit to the Division of Dockets 

Management written or electronic 

comments by (see DATES). Two copies of 

any written comments are to be 

submitted, except that individuals may 

submit one copy. Comments are to be 

identified with the docket number 

found in brackets in the heading of this 

document. Received comments may be 

seen in the Division of Dockets 

Management between 9 a.m. and 4 p.m., 

Monday through Friday. FDA will also 

place on public display any 

amendments to, or comments on, the 

petitioner’s environmental assessment 

without further announcement in the 

Federal Register. If, based on its review, 

the agency finds that an environmental 

impact statement is not required, and 

this petition results in a regulation, the 

notice of availability of the agency’s 

finding of no significant impact and the 

evidence supporting that finding will be 

published with the regulation in the 

Federal Register in accordance with 21 

CFR 25.51(b). 

Dated: October 17, 2006. 

Laura M. Tarantino, 

Director, Office of Food Additive Safety, 

Center for Food Safety and Applied Nutrition. 

[FR Doc. E6–17834 Filed 10–24–06; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Agency Information Collection 

Activities: Submission for OMB 

Review; Comment Request 

Periodically, the Health Resources 

and Services Administration (HRSA) 

publishes abstracts of information 

collection requests under review by the 

Office of Management and Budget 

(OMB), in compliance with the 

Paperwork Reduction Act of 1995 (44 

U.S.C. Chapter 35). To request a copy of 

the clearance requests submitted to 

OMB for review, call the HRSA Reports 

Clearance Office on (301)–443–1129. 

The following request has been 

submitted to the Office of Management 

and Budget for review under the 

Paperwork Reduction Act of 1995: 

Proposed Project: Grants for Hospital 

Construction and Modernization—

Federal Right of Recovery and Waiver 

of Recovery (42 CFR Part 124, Subpart 

H) (OMB No. 0915–0099Extension) 

The regulation known as ‘‘Federal 

Right of Recovery and Waiver of 

Recovery,’’ provides a means for the 

Federal Government to recover grant 

funds and a method of calculating 

interest when a grant-assisted facility 

under Titles VI and XVI of the Public 

Health Service Act is sold or leased, or 

there is a change in use of the facility. 

It also allows for a waiver of the right 

of recovery under certain circumstances. 

Facilities are required to provide written 

notice to the Federal Government when 

such a change occurs and to provide 

copies of sales contracts, lease 

agreements, estimates of current assets 

and liabilities, value of equipment, 

expected value of land on the new 

owner’s books and remaining 

depreciation for all fixed assets involved 

in the transactions, and other 

information and documents pertinent to 

the change of status. 

Estimates of annualized burden are as 

follows: 

mstockstill on PROD1PC61 with NOTICES